Isabelle Ariane Bley

Dr. Isabelle Ariane Bley

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
TMTobias Mohr
Tobias Mohr
AZAnabel Zwick
Anabel Zwick
MHMuriel Charlotte Hans
Muriel Charlotte Hans
IBIsabelle Ariane Bley
Isabelle Ariane Bley
FBFelix Leon Braun
Felix Leon Braun
SLStefan Lohse
Stefan Lohse
Currently, no established biomarkers are recommended for the routine diagnosis of penile carcinoma (PeCa). The rising incidence of this human papillomavirus (HPV)–related cancer entity highlights the need for promising candidates. The Calprotectin subunits S100A8 and S100A9 mark myeloid-derived suppressor cells in other HPV-related entities while their receptor CD147 was discussed to identify patients with PeCa at a higher risk for poor prognoses and treatment failure. We thus examined their expression using immunohistochemistry staining of PeCa specimens from 74 patients on tissue microarrays of the tumor center, the invasion front, and lymph node metastases. Notably, whereas the tumor center was significantly more intensively stained than the invasion front, lymph node metastases were thoroughly positive for both S100 subunits. An HPV-positive status combined with an S100A8+S100A9+ profile was related with an elevated risk for metastases. We observed several PeCa specimens with S100A8+S100A9+-infiltrating immune cells overlapping with CD15 marking neutrophils. The S100A8+S100A9+CD15+ profile was associated with dedifferentiated and metastasizing PeCa, predominantly of HPV-associated subtype. These data suggest a contribution of neutrophil-derived suppressor cells to the progression of HPV-driven penile carcinogenesis. CD147 was elevated, expressed in PeCa specimens, prominently at the tumor center and in HPV-positive PeCa cell lines. CD147+HPV+ PeCa specimens were with the higher-frequency metastasizing cancers. Moreover, an elevated expression of CD147 of HPV-positive PeCa cell lines correlated negatively with the susceptibility to IgA-based neutrophil-mediated tumor cell killing. Finally, stratifying patients regarding their HPV/S100A8/S100A9/CD15/CD147 profile may help identify patients with progressing cancer and tailor immunotherapeutic treatment strategies.

10 November 2021 in Translational Oncology
Verified
Journal Article
Open access
IBIsabelle Ariane Bley
Isabelle Ariane Bley
AZAnabel Zwick
Anabel Zwick
MHMuriel Charlotte Hans
Muriel Charlotte Hans
KTKatrin Thieser
Katrin Thieser
VWViktoria Wagner
Viktoria Wagner
SLStefan Lohse
Stefan Lohse
• Elevated expression of Wnt pathway associated factors in HPV-positive penile cancer cells. • lacking nuclear beta-catenin translocation indicated an actively abrogated Wnt signaling. • elevated expression of the Wnt antagonist DKK1 in HPV-positive penile cancer cells. • DKK1-driven autocrine Wnt pathway inhibition in penile cancer cells. • DKK1+ penile cancers are with a higher frequency HPV+, less differentiated and grow more aggressively.

3 May 2025 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
WJWiebke Jünemann
Wiebke Jünemann
IBIsabelle Ariane Bley
Isabelle Ariane Bley
LRLaura Rekowski
Laura Rekowski
MKMarianne Klokow
Marianne Klokow
SHSusanne Herppich
Susanne Herppich
KCKerstin Cornils
Kerstin Cornils
Immunotherapy by inhibition of immune checkpoint (IC) molecules has emerged as an important cancer therapy. Among these lC, the poliovirus receptor/poliovirus receptor-like 2 protein (PVR/PVRL2)-TIGIT axis was discovered as potential target for various cancers. For neuroblastoma (NB), the most common extracranial solid cancer in children, no effective IC therapy has been established yet. To investigate the PVR/PVRL2-TIGIT IC axis as a new target for the treatment of NB, we analysed whether PVR and PVRL2 influence the survival of patients and verified the expression of the receptors on NB cell lines. To disrupt the checkpoint axis, we performed single and double knockouts of these receptors on NB cell lines and subsequently removed TIGIT, an inhibitory receptor on immune effector cells, from NK-92 cells. Finally, we combined checkpoint inhibition with GD2-CAR NK-92 cells and investigated changes in cytotoxicity. Using RNA-Seq data we showed that the expression of PVR and PVRL2 on NB cells correlates to a lower event-free survival of patients. CRISPR/Cas9 knockouts of PVR and PVRL2 showed no improved cytotoxic activity of NK-92 cells. We observed enhanced lysis of NB cells using TIGIT-deficient NK-92 cells. However, the cytotoxicity of GD2-CAR NK-92 was not significantly enhanced. In summary, we have shown that in addition to the interaction of PVR/PVRL2 and TIGIT on engineered immune effector cells against NB, pleiotropic ligands appear to be relevant. Deletion of TIGIT from immune effector cells is a promising approach to protect these cells from tumour-associated inhibitory signals but cannot enhance the effect of GD2-CAR-NK-92 cells.

27 September 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SLStefan Lohse
Stefan Lohse
JMJan Niklas Mink
Jan Niklas Mink
LELea Eckhart
Lea Eckhart
MHMuriel Charlotte Hans
Muriel Charlotte Hans
LJLeuart Jusufi
Leuart Jusufi
KJKerstin Junker
Kerstin Junker
PeCa is a rare entity with rising incidence rates due to increased infections with human papillomaviruses (HPV). The distinct subtypes of PeCa with an individual pathogenesis demand biomarkers for a precise patient risk assessment regarding disease progression and therapeutic susceptibility. We recently identified promising candidates associated with an HPV-instructed tumor microenvironment (TME) using HPV-positive PeCa cell lines and tissue microarrays (TMA). The capacity of HPV + p63 + PeCa cells to release neutrophil-attracting CXCL-8 provided a molecular link explaining the infiltration of CD15 + myeloid cells in PeCa specimens. The candidate biomarkers HPV, p63, CD15, DKK1, and CD147 linked a tumor-promoting TME with a higher TNM classification reflecting more aggressive and metastasizing cancers. Based on immune-reactive scores (IRS) from TMA staining for these biomarkers, we calculated correlations and conducted association analyses to assess the degree of relationship between all biomarkers. We then conducted Kaplan–Meier survival estimates and Cox regression analyses to delineate the impact on PeCa patient survival. There is a notable predictive potential regarding the survival of patients with biomarker profiles beyond the potency of the individual biomarker. From all candidate biomarkers and biomarker profiles, the combination of CD147 and infiltrating CD15 + cells linked to an active HPV-driven transformation displayed cancer-immune dynamics with dismal prognosis for patients. After deciphering relevant interdependencies, the HPV + CD147 + CD15 + status was the most potent profile predicting metastasis-free survival of PeCa patients. The results of this report underscore the need for analysis of the TME and the development of multi-parameter composite scores that reflect fundamental cancer-immune relationships to tailor therapeutic interventions based on actual cancer immune dynamics.

5 November 2021 in Hereditas
Verified
Journal Article
Open access
PDF file
CKChristine Klöppel
Christine Klöppel
KHKirsten Hildebrandt
Kirsten Hildebrandt
DKDieter Kolb
Dieter Kolb
NFNora Fürst
Nora Fürst
IBIsabelle Ariane Bley
Isabelle Ariane Bley
UWUwe Walldorf
Uwe Walldorf
Background: TheDrosophilabrain is an ideal model system to study stem cells, here called neuroblasts, and the generation of neural lineages. Many transcriptional activators are involved in formation of the brain during the development ofDrosophila melanogaster. The transcription factorDrosophilaRetinal homeobox (DRx), a member of the 57B homeobox gene cluster, is also one of these factors for brain development.Results: In this study a detailed expression analysis of DRx in different developmental stages was conducted. We show that DRx is expressed in the embryonic brain in the protocerebrum, in the larval brain in the DM and DL lineages, the medulla and the lobula complex and in the central complex of the adult brain. We generated a DRx enhancer trap strain by gene targeting and reintegration of Gal4, which mimics the endogenous expression of DRx. With the help of eight existing enhancer-Gal4 strains and one made by our group, we mapped various enhancers necessary for the expression of DRx during all stages of brain development from the embryo to the adult. We made an analysis of some larger enhancer regions by gene targeting. Deletion of three of these enhancers showing the most prominent expression patterns in the brain resulted in specific temporal and spatial loss of DRx expression in defined brain structures.Conclusion: Our data show that DRx is expressed in specific neuroblasts and defined neural lineages and suggest that DRx is another important factor forDrosophilabrain development.

15 January 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IBIsabelle Ariane Bley
Isabelle Ariane Bley
SBStefan Behrens
Stefan Behrens
MSMichael Spohn
Michael Spohn
IMIngo Müller
Ingo Müller
BSBenjamin Schattling
Benjamin Schattling
Background/Objectives: Neuroblastoma is a highly aggressive pediatric cancer that arises from immature nerve cells and exhibits a broad spectrum of clinical presentations. While low- and intermediate-risk neuroblastomas often have favorable outcomes, high-risk neuroblastomas are associated with poor prognosis and significant treatment challenges. The complex genetic networks driving these high-risk cases remain poorly understood. This study aims to investigate differences in gene expression patterns that may contribute to disease outcomes. Methods: We employed an in silico approach to analyze a cohort of 493 neuroblastoma tumor samples that underwent mRNA sequencing (GSE49711). This dataset was reanalyzed in depth with a non-hypothesis-driven approach to identify the expression patterns and regulatory mechanisms associated with a poor prognosis. Results: By exploring global gene expression and the integration of clinical parameters, we stratified the samples into two groups with highly distinct gene expression profiles. MYCN amplification emerged as a major driver not only of poor prognosis but also of specific gene regulatory patterns. Notably, tumors with MYCN amplification exhibited the strong regulation of immune response genes and less immune infiltration, suggesting potential immune evasion. However, while we observed only minor changes in immune checkpoint expression, there was a strong modulation of glycosyltransferase genes in MYCN-amplified tumors. Using this information, we were able to construct a risk profile based on 12 glycosylation-related genes, which correlates with the survival outcomes of neuroblastoma patients. Conclusions: This study highlights the role of MYCN amplification in driving a poor prognosis in neuroblastoma through the regulation of immune response and glycosylation-related genes. Based on this finding, we developed a genetic risk profile that correlates with survival outcomes in neuroblastoma patients.